J. Nicholas Brenton

Dr. J. Nicholas Brenton

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2013 in Epilepsia
Verified
Journal Article
Open access
PDF file
NGNicolas Gaspard
Nicolas Gaspard
BFBrandon Foreman
Brandon Foreman
LJLilith M Judd
Lilith M Judd
JBJ. Nicholas Brenton
J. Nicholas Brenton
BNBarnett R Nathan
Barnett R Nathan
SLSuzette M Laroche
Suzette M Laroche
Summary: Purpose: To examine patterns of use, efficacy, and safety of intravenous ketamine for the treatment of refractory status epilepticus (RSE).Methods: Multicenter retrospective review of medical records and electroencephalography (EEG) reports in 10 academic medical centers in North America and Europe, including 58 subjects, representing 60 episodes of RSE that were identified between 1999 and 2012. Seven episodes occurred after anoxic brain injury.Key Findings: Permanent control of RSE was achieved in 57% (34 of 60) of episodes. Ketamine was felt to have contributed to permanent control (“possible” or “likely” responses) in 32% (19 of 60) including seven (12%) in which ketamine was the last drug added (likely responses). Four of the seven likely responses, but none of the 12 possible ones, occurred in patients with postanoxic brain injury. No likely responses were observed when infusion rates were lower than 0.9 mg/kg/h, when ketamine was introduced at least 8 days after SE onset, or after failure of seven or more drugs. Ketamine was discontinued due to possible adverse events in five patients. Complications were mostly attributed to concurrent drugs, especially other anesthetics. Mortality rate was 43% (26 of 60), but was lower when SE was controlled within 24 h of ketamine initiation (16% vs. 56%, p = 0.0047).Significance: Ketamine appears to be a relatively effective and safe drug for the treatment of RSE. This retrospective series provides preliminary data on effective dose and appropriate time of intervention to aid in the design of a prospective trial to further define the role of ketamine in the treatment of RSE.

1 April 2018 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
MGMarina Gaínza-Lein
Marina Gaínza-Lein
IFIván Sánchez Fernández
Iván Sánchez Fernández
MJMichele Jackson
Michele Jackson
NANicholas S. Abend
Nicholas S. Abend
RARavindra Arya
Ravindra Arya
FGfor the Pediatric Status Epilepticus Research Group
for the Pediatric Status Epilepticus Research Group
Status epilepticus (SE) consists of a prolonged, self-sustaining seizure or repeated seizures without return to baseline neurological function.1 It is one of the most frequent life-threatening emergencies affecting approximately 17 to 23 per 100 000 children in the United States and Europe.2-4 The short-term mortality ranges from 3% to 9%,2,5 and the long-term mortality rate is 7%.5 Survivors of SE often have long-term sequelae, including cognitive and neurodevelopmental impairment, epilepsy, and recurrent SE.6-8

9 June 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
IFIván Sánchez Fernández
Iván Sánchez Fernández
NANicholas S Abend
Nicholas S Abend
SASatish Agadi
Satish Agadi
SASookee An
Sookee An
RARavindra Arya
Ravindra Arya
P(Pediatric Status Epilepticus Research Group (pSERG)
Pediatric Status Epilepticus Research Group (pSERG)
Objective: To describe the time elapsed from onset of pediatric convulsive status epilepticus (SE) to administration of antiepileptic drug (AED). Methods: This was a prospective observational cohort study performed from June 2011 to June 2013. Pediatric patients (1 month–21 years) with convulsive SE were enrolled. In order to study timing of AED administration during all stages of SE, we restricted our study population to patients who failed 2 or more AED classes or needed continuous infusions to terminate convulsive SE. Results: We enrolled 81 patients (44 male) with a median age of 3.6 years. The first, second, and third AED doses were administered at a median (p25–p75) time of 28 (6–67) minutes, 40 (20–85) minutes, and 59 (30–120) minutes after SE onset. Considering AED classes, the initial AED was a benzodiazepine in 78 (96.3%) patients and 2 (2–3) doses of benzodiazepines were administered before switching to nonbenzodiazepine AEDs. The first and second doses of nonbenzodiazepine AEDs were administered at 69 (40–120) minutes and 120 (75–296) minutes. In the 64 patients with out-of-hospital SE onset, 40 (62.5%) patients did not receive any AED before hospital arrival. In the hospital setting, the first and second in-hospital AED doses were given at 8 (5–15) minutes and 16 (10–40) minutes after SE onset (for patients with in-hospital SE onset) or after hospital arrival (for patients with out-of-hospital SE onset). Conclusions: The time elapsed from SE onset to AED administration and escalation from one class of AED to another is delayed, both in the prehospital and in-hospital settings.

1 July 2019 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
JBJ. Nicholas Brenton
J. Nicholas Brenton
BBBrenda Banwell
Brenda Banwell
ABA.G. Christina Bergqvist
A.G. Christina Bergqvist
DLDiana Lehner-Gulotta
Diana Lehner-Gulotta
LGLauren Gampper
Lauren Gampper
MGMyla D. Goldman
Myla D. Goldman
Objective To assess the safety and tolerability of a modified Atkins diet (KDMAD), a type of ketogenic diet (KD), in subjects with relapsing MS while exploring potential benefits of KDs in MS. Methods Twenty subjects with relapsing MS enrolled into a 6-month, single-arm, open-label study of the KDMAD. Adherence to KDMAD was objectively monitored by daily urine ketone testing. Fatigue and depression scores and fasting adipokines were obtained at baseline and on diet. Brain MRI was obtained at baseline and 6 months. Intention to treat was used for primary data analysis, and a per-protocol approach was used for secondary analysis. Results No subject experienced worsening disease on diet. Nineteen subjects (95%) adhered to KDMAD for 3 months and 15 (75%) adhered for 6 months. Anthropometric improvements were noted on KDMAD, with reductions in body mass index and total fat mass (p < 0.0001). Fatigue (p = 0.002) and depression scores (p = 0.003) were improved. Serologic leptin was significantly lower at 3 months (p < 0.0001) on diet. Conclusions KDMAD is safe, feasible to study, and well tolerated in subjects with relapsing MS. KDMAD improves fatigue and depression while also promoting weight loss and reducing serologic proinflammatory adipokines. Classification of evidence The study is rated Class IV because of the absence of a non-KD control group.

13 April 2022 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
JBJ. Nicholas Brenton
J. Nicholas Brenton
DLDiana Lehner-Gulotta
Diana Lehner-Gulotta
EWEmma Woolbright
Emma Woolbright
BBBrenda Banwell
Brenda Banwell
ABA G Christina Bergqvist
A G Christina Bergqvist
MGMyla D Goldman
Myla D Goldman
Background Dietary changes impact human physiology and immune function and have potential as therapeutic strategies. Objective Assess the tolerability of a ketogenic diet (KD) in patients with relapsing multiple sclerosis (MS) and define the impact on laboratory and clinical outcome metrics. Methods Sixty-five subjects with relapsing MS enrolled into a 6-month prospective, intention-to-treat KD intervention. Adherence was monitored with daily urine ketone testing. At baseline, fatigue, depression and quality of life (QoL) scores were obtained in addition to fasting adipokines and MS-related clinical outcome metrics. Baseline metrics were repeated at 3 and/or 6 months on-diet. Results Eighty-three percent of participants adhered to the KD for the study duration. Subjects exhibited significant reductions in fat mass and showed a nearly 50% decline in self-reported fatigue and depression scores. MS QoL physical health (67±16 vs 79±12, p<0.001) and mental health (71±17 vs 82±11, p<0.001) composite scores increased on-diet. Significant improvements were noted in Expanded Disability Status Scale scores (2.3±0.9 vs 1.9±1.1, p<0.001), 6-minute walk (1631±302 vs 1733±330 ft, p<0.001) and Nine-Hole Peg Test (21.5±3.6 vs 20.3±3.7 s, p<0.001). Serum leptin was lower (25.5±15.7 vs 14.0±11.7 ng/mL, p<0.001) and adiponectin was higher (11.4±7.8 vs 13.5±8.4 µg/mL, p=0.002) on the KD. Conclusion KDs are safe and tolerable over a 6-month study period and yield improvements in body composition, fatigue, depression, QoL, neurological disability and adipose-related inflammation in persons living with relapsing MS. Trial registration information Registered on ClinicalTrials.gov under registration number NCT03718247, posted on 24 October 2018. First patient enrolment date: 1 November 2018. Link: https://clinicaltrials.gov/ct2/show/NCT03718247?term=NCT03718247&draw=2&rank=1.

1 July 2016 in Pediatric Neurology
Verified
Journal Article
Closed access
JBJ. Nicholas Brenton
J. Nicholas Brenton
HGHoward P. Goodkin
Howard P. Goodkin